Want to see AU:ZLD full AI Analyst Report?
ZLD Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$1.15
Previous CloseN/A
Volume190.00
Average Volume (3M)1.92K
Market Cap
AU$5.95M
Enterprise ValueAU$8.08M
Total Cash (Recent Filing)AU$5.66K
Total Debt (Recent Filing)AU$2.14M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Monetization StrategyA dual strategy of product commercialization plus licensing and co-development creates durable optionality: sales channels can generate recurring revenue while licensing yields high-margin, scalable income and milestone payments. Over months this mix can stabilize cash flow if partnerships are executed.
Cannabinoid R&D And Product FocusA focused portfolio in cannabinoid therapeutics and consumer health aligns with structural industry tailwinds (medical cannabis acceptance, wellness demand). Proprietary formulations and clinical development create potential for defensible niche products and licensing revenue over the medium term if evidence and regulatory paths progress.
Lean Operating StructureA very small headcount implies a lean cost base and potential runway advantage relative to larger peers; this enables prioritization of R&D or commercial investments and reliance on outsourcing/partners. Over several months a low fixed-cost structure can reduce cash burn and preserve capital to advance key assets.
Bears Say
Severe Revenue DeclineA near-total collapse in reported revenue is a durable red flag: it limits internal funding for R&D and commercialization, weakens negotiating leverage with partners, and raises the bar for organic recovery. Restoring meaningful top-line requires material commercial or partnership breakthroughs.
Negative Shareholders' EquityNegative equity signals balance-sheet impairment and constrains access to traditional financing; lenders and partners may demand stricter terms or collateral. Over months this increases default and dilution risk, forcing reliance on equity raises or asset sales to fund operations and strategic initiatives.
Negative Operating And Free Cash FlowsPersistent negative operating and free cash flow erode reserves and necessitate external funding. Even with slight FCF improvement, ongoing cash burn pressures strategic flexibility, increases likelihood of dilutive financing, and can delay development/commercial milestones absent reliable partner or funding commitments.
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.31 and its highest was AU$1.15 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is AU$5.95M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 63 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―